Market research
MDNA.TO Medicenna Therapeutics Corp
TO CAD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 42M
- P/E ratio
- Not available
- Analyst target
- 3.2
- Dividend yield
- Not available
- Beta
- 2.1
Profile
Instrument facts
- Exchange
- TO
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA58490H1073
- Market cap
- 42M
- P/E ratio
- Not available
- Analyst target
- 3.2
- Dividend yield
- Not available
- Beta
- 2.1
About
About Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
Research context
Medicenna Therapeutics Corp appears in PyInvesting’s Toronto Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- CAD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the MDNA.TO discussion.
5 years, 6 months ago
Medicenna Therapeutics Corp is currently in a long term downtrend where the price is trading 24.0% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Medicenna Therapeutics Corp's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 123.4% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 94.2% to $-4M since the same quarter in the previous year.
Based on the above factors, Medicenna Therapeutics Corp gets an overall score of 1/5.